Mitoxantrone plus Cytarabine versus Daunorubicin plus Cytarabine as Induction Therapy for Previously Untreated Adult Patients with Acute Myeloid Leukemia

Content Provider	Semantic Scholar
Author	Nikanfar, Alireza Asvadi, Iraj Vaez, Jalil
Copyright Year	2007
Abstract	Objective: The aim of this study was to evaluate the efficacy of mitoxantrone versus daunorubicin on the response rates of acute myeloid leukemia (AML) patients. Methodology: In this prospective randomized trial, adult patients with newly diagnosed AML received daunorubicin(45mg/m²/d for 3 days) or mitoxantrone (12mg/m²/d for 3 days), each combined with the identical dose of cytarabine(ara-c) (150mg/m²/d by continuous infusion for 7 days). Of 27 patients, 10 were randomly allocated to the mitoxantrone plus ara-c “MA” treatment arm and 17 to the daunorubicin plus ara-c “DA” treatment arm. Results: Median age of the patients in MA was18 years and in DA was 25. Fifty percent of the MA achieved complete remission and 40% achieved a partial remission giving an overall response rate of %90. The same overall response rate was significantly lower in DA group (P=0.025). Conclusion: The combination of mitoxantrone and ara-c is a possible alternative to daunorubicin and ara-c combination for the treatment of AML.
File Format	PDF HTM / HTML
Alternate Webpage(s)	https://www.pjms.com.pk/issues/octdec207/pdf/mitoxantrone.pdf
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article